drugset / Trial / NCT06025110
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
RandomizedSequentialSingle-blindTreatment
Summary
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
Timeline
- Start
- 2023-01-23
- Primary completion
- 2025-07-24
- Completion
- 2025-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | — | — |